Extended Data Fig. 5: TCRβ diversity, but not number of TCR-specific motifs, shows a trend toward improved PFS in children treated with atezolizumab. | Nature Cancer

Extended Data Fig. 5: TCRβ diversity, but not number of TCR-specific motifs, shows a trend toward improved PFS in children treated with atezolizumab.

From: Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab

Extended Data Fig. 5

(A) Multivariable analysis using Cox proportional hazards model adjusted for sample origin excluding those that originated from lymph nodes (two-sided Wald test, N = 34 patients). Center indicates hazard ratio and lines indicate confidence intervals. (B) TCRβ diversity is positively correlated with the number of TCRβ-specific motifs derived using the GLIPH2 algorithm. Value denotes Spearman r (N = 45 samples). (C) Kaplan–Meier analysis revealed no significant associations between PFS and the number of TCRβ-specific motifs (log-rank test, N = 42 patients). (D) Heat map depicting Spearman correlations among TCRβ diversity and immune-cell estimates from CIBERSORT in solid tumors excluding samples taken from lymph nodes (N = 33 samples). TCRβ diversity is shown in bold.

Back to article page